| Quynh Tram Do, MD | |
|
7474 S Kirkwood Rd Ste 104, Houston, TX 77072-3349 | |
| (281) 495-7534 | |
| Not Available |
| Full Name | Quynh Tram Do |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 23 Years |
| Location | 7474 S Kirkwood Rd Ste 104, Houston, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114118593 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | L8043 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hca Houston Healthcare West | Houston, TX | Hospital |
| Houston Methodist West Hospital | Houston, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Villagemd Of Southeast Texas Pa | 4587947346 | 271 |
News Archive
Finesse Solutions, Inc., a manufacturer of measurement and control solutions for life sciences process applications, announced the launch of its new SmartParts™ family of intelligent transmitters and actuators.
Neuroscientists at Georgetown University Medical Center and Germany's Technische Universität München say they've uncovered the brain malady responsible for tinnitus and for chronic pain — the uncomfortable, sometimes agonizing sensations that persist long after an initial injury.
Boston Scientific Corporation has welcomed three-year results from the SPIRIT II Clinical Trial and a pooled meta-analysis of two-year data from the SPIRIT II and III Trials.
Enobia Pharma today announced positive interim data from a clinical study of ENB-0040, a bone targeted enzyme replacement therapy, under investigation for the treatment of hypophosphatasia (HPP). After 12 weeks of treatment with ENB-0040, children with HPP showed marked improvements in bone mineralization and function including increases in strength, endurance and mobility and reduction in pain. These findings were presented by Dr. Michael Whyte at ENDO 2010, the 92nd Annual Meeting of The Endocrine Society.
St. Jude Medical, Inc. today announced European CE Mark approval and first implants of its Fortify™ and Fortify ST implantable cardioverter defibrillators (ICD) and Unify™ cardiac resynchronization therapy defibrillator (CRT-D). The devices will be fully launched in Europe later this spring, and U.S. versions of the Fortify ICD and Unify CRT-D are expected to be launched later this year. The reduced size of these new devices compared to those of previous generations creates the smallest available device footprint in the industry.
› Verified 2 days ago
| Entity Name | Villagemd Of Southeast Texas Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841643327 PECOS PAC ID: 4587947346 Enrollment ID: O20170202000474 |
News Archive
Finesse Solutions, Inc., a manufacturer of measurement and control solutions for life sciences process applications, announced the launch of its new SmartParts™ family of intelligent transmitters and actuators.
Neuroscientists at Georgetown University Medical Center and Germany's Technische Universität München say they've uncovered the brain malady responsible for tinnitus and for chronic pain — the uncomfortable, sometimes agonizing sensations that persist long after an initial injury.
Boston Scientific Corporation has welcomed three-year results from the SPIRIT II Clinical Trial and a pooled meta-analysis of two-year data from the SPIRIT II and III Trials.
Enobia Pharma today announced positive interim data from a clinical study of ENB-0040, a bone targeted enzyme replacement therapy, under investigation for the treatment of hypophosphatasia (HPP). After 12 weeks of treatment with ENB-0040, children with HPP showed marked improvements in bone mineralization and function including increases in strength, endurance and mobility and reduction in pain. These findings were presented by Dr. Michael Whyte at ENDO 2010, the 92nd Annual Meeting of The Endocrine Society.
St. Jude Medical, Inc. today announced European CE Mark approval and first implants of its Fortify™ and Fortify ST implantable cardioverter defibrillators (ICD) and Unify™ cardiac resynchronization therapy defibrillator (CRT-D). The devices will be fully launched in Europe later this spring, and U.S. versions of the Fortify ICD and Unify CRT-D are expected to be launched later this year. The reduced size of these new devices compared to those of previous generations creates the smallest available device footprint in the industry.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Quynh Tram Do, MD 7474 S Kirkwood Rd Ste 104, Houston, TX 77072-3349 Ph: (281) 495-7534 | Quynh Tram Do, MD 7474 S Kirkwood Rd Ste 104, Houston, TX 77072-3349 Ph: (281) 495-7534 |
News Archive
Finesse Solutions, Inc., a manufacturer of measurement and control solutions for life sciences process applications, announced the launch of its new SmartParts™ family of intelligent transmitters and actuators.
Neuroscientists at Georgetown University Medical Center and Germany's Technische Universität München say they've uncovered the brain malady responsible for tinnitus and for chronic pain — the uncomfortable, sometimes agonizing sensations that persist long after an initial injury.
Boston Scientific Corporation has welcomed three-year results from the SPIRIT II Clinical Trial and a pooled meta-analysis of two-year data from the SPIRIT II and III Trials.
Enobia Pharma today announced positive interim data from a clinical study of ENB-0040, a bone targeted enzyme replacement therapy, under investigation for the treatment of hypophosphatasia (HPP). After 12 weeks of treatment with ENB-0040, children with HPP showed marked improvements in bone mineralization and function including increases in strength, endurance and mobility and reduction in pain. These findings were presented by Dr. Michael Whyte at ENDO 2010, the 92nd Annual Meeting of The Endocrine Society.
St. Jude Medical, Inc. today announced European CE Mark approval and first implants of its Fortify™ and Fortify ST implantable cardioverter defibrillators (ICD) and Unify™ cardiac resynchronization therapy defibrillator (CRT-D). The devices will be fully launched in Europe later this spring, and U.S. versions of the Fortify ICD and Unify CRT-D are expected to be launched later this year. The reduced size of these new devices compared to those of previous generations creates the smallest available device footprint in the industry.
› Verified 2 days ago
Dr. Jeanette Ferrer, D.O Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6565 Fannin St., Main 577, Houston, TX 77030 Phone: 713-441-0428 | |
Dr. Bhavik Kumar, MD, MPH Family Medicine Medicare: Medicare Enrolled Practice Location: 4600 Gulf Fwy, Houston, TX 77023 Phone: 713-522-3976 Fax: 404-494-7435 | |
Nneka Okafor, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3701 Kirby Dr Ste 600, Houston, TX 77098 Phone: 713-798-8072 | |
Dr. Rolando R Maldonado I, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 548 Waugh Dr, Houston, TX 77019 Phone: 713-933-0501 | |
Scott H Hung, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 10950 Resource Pkwy, Suite A, Houston, TX 77089 Phone: 281-484-5587 Fax: 281-506-1013 | |
Michael E. Buxbaum, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3100 Weslayan St Ste 350, Houston, TX 77027 Phone: 713-533-1700 Fax: 713-533-1708 | |
Diana Atwal, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6630 De Moss Dr, Houston, TX 77074 Phone: 713-272-2600 Fax: 713-272-5589 |